Literature DB >> 30810870

A response to "Personalised medicine and population health: breast and ovarian cancer".

Antonis Antoniou1, Hoda Anton-Culver2, Alexander Borowsky3, Mireille Broeders4, Jennifer Brooks5, Anna Chiarelli5, Jocelyne Chiquette6, Jack Cuzick7, Suzette Delaloge8, Peter Devilee9, Michael Dorval6, Douglas Easton1, Andrea Eisen10, Martin Eklund11, Laurence Eloy6, Laura Esserman12, Montserrat Garcia-Closas13, David Goldgar14, Per Hall11, Bartha Maria Knoppers15, Peter Kraft16, Andrea La Croix17, Lisa Madalensky17, Nasim Mavaddat1, Nicole Mittman18, Hermann Nabi6, Olufunmilayo Olopade19, Nora Pashayan20, Marjanka Schmidt21, Yiwey Shieh22, Jacques Simard6, Allison Stover-Fiscallini22, Jeffrey A Tice22, Laura Van't Veer22, Neil Wenger23, Michael Wolfson24, Christina Yau22, Elad Ziv22.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30810870      PMCID： PMC8207533          DOI： 10.1007/s00439-019-01984-z

Source DB:  PubMed          Journal:  Hum Genet        ISSN： 0340-6717            Impact factor:   4.132


× No keyword cloud information.
  7 in total

1.  Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.

Authors:  Sarah J Nyante; Mark E Sherman; Ruth M Pfeiffer; Amy Berrington de Gonzalez; Louise A Brinton; Erin J Aiello Bowles; Robert N Hoover; Andrew Glass; Gretchen L Gierach
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

2.  Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.

Authors:  Jack Cuzick; Jane Warwick; Elizabeth Pinney; Stephen W Duffy; Simon Cawthorn; Anthony Howell; John F Forbes; Ruth M L Warren
Journal:  J Natl Cancer Inst       Date:  2011-04-11       Impact factor: 13.506

3.  Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.

Authors:  Jingmei Li; Keith Humphreys; Louise Eriksson; Gustaf Edgren; Kamila Czene; Per Hall
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

4.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

5.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

Review 6.  The WISDOM Study: breaking the deadlock in the breast cancer screening debate.

Authors:  Laura J Esserman
Journal:  NPJ Breast Cancer       Date:  2017-09-13

7.  Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

Authors:  Nora Pashayan; Steve Morris; Fiona J Gilbert; Paul D P Pharoah
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777
  7 in total
  6 in total

1.  Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.

Authors:  Amber N Hurson; Parichoy Pal Choudhury; Chi Gao; Anika Hüsing; Mikael Eriksson; Min Shi; Michael E Jones; D Gareth R Evans; Roger L Milne; Mia M Gaudet; Celine M Vachon; Daniel I Chasman; Douglas F Easton; Marjanka K Schmidt; Peter Kraft; Montserrat Garcia-Closas; Nilanjan Chatterjee
Journal:  Int J Epidemiol       Date:  2021-03-23       Impact factor: 9.685

2.  Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines.

Authors:  Gretchen L Gierach; Parichoy Pal Choudhury; Montserrat García-Closas
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

3.  Implementation considerations for offering personal genomic risk information to the public: a qualitative study.

Authors:  Amelia K Smit; Gillian Reyes-Marcelino; Louise Keogh; Kate Dunlop; Ainsley J Newson; Anne E Cust
Journal:  BMC Public Health       Date:  2020-06-29       Impact factor: 3.295

4.  Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada.

Authors:  Cynthia Mbuya Bienge; Nora Pashayan; Jennifer D Brooks; Michel Dorval; Jocelyne Chiquette; Laurence Eloy; Annie Turgeon; Laurence Lambert-Côté; Jean-Sébastien Paquette; Emmanuelle Lévesque; Julie Hagan; Meghan J Walker; Julie Lapointe; Gratien Dalpé; Palmira Granados Granados Moreno; Kristina Blackmore; Michael Wolfson; Yann Joly; Mireille Broeders; Bartha M Knoppers; Anna M Chiarelli; Jacques Simard; Hermann Nabi
Journal:  J Pers Med       Date:  2021-02-02

5.  Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.

Authors:  Vassiliki Kotoula; Kyriaki Papadopoulou; Ioannis Tikas; Florentia Fostira; Eleni Vrettou; Sofia Chrisafi; Elena Fountzilas; Georgia-Angeliki Koliou; Paraskevi Apostolou; Konstantinos Papazisis; Thomas Zaramboukas; Anthoula Asimaki-Vlachopoulou; Spyros Miliaras; Ananias Ananiadis; Christos Poulios; Ioannis Natsiopoulos; Aris Tsiftsoglou; Efterpi Demiri; George Fountzilas
Journal:  Breast Cancer       Date:  2021-07-24       Impact factor: 4.239

Review 6.  Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field.

Authors:  Tatiane Yanes; Mary-Anne Young; Bettina Meiser; Paul A James
Journal:  Breast Cancer Res       Date:  2020-02-17       Impact factor: 6.466
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.